One of Oncology’s Biggest Challenges Remains Unsolved
Many cancer therapies fail to reach sufficient concentrations within solid tumors, limiting therapeutic effectiveness and increasing systemic exposure.
The Science Behind OncoLipoMab
OncoLipoMab is developing a novel IgM-enabled drug delivery designed to improve therapeutic accumulation within solid tumors.
Contact us
Connect with our scientific partnerships team to discuss partnerships, collaborations, licensing, or integrating Oncolipomab into your oncology pipeline.
Subscribe
Get OncoLipoMab’s latest releases, delivery updates, and event invitations.